HC Wainwright Has Bearish Outlook for ATOS FY2026 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Atossa Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.32) per share for the year, down from their previous estimate of ($0.21). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

A number of other research analysts have also recently weighed in on the stock. Ascendiant Capital Markets lifted their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th.

Atossa Therapeutics Price Performance

ATOS opened at $1.28 on Friday. The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.38. Atossa Therapeutics has a 1 year low of $0.65 and a 1 year high of $2.31. The stock has a market cap of $160.97 million, a P/E ratio of -5.82 and a beta of 1.23.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the period. Cetera Advisors LLC acquired a new stake in Atossa Therapeutics in the 1st quarter worth about $72,000. Virtu Financial LLC acquired a new stake in Atossa Therapeutics in the 1st quarter worth about $151,000. Rhumbline Advisers purchased a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $161,000. Finally, Vanguard Group Inc. raised its holdings in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after acquiring an additional 78,269 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.